Find Clinical Trials

← Back
February 9, 2026 in Genitourinary (GU)

GU015: The Phase III Adaptive Radiation And Chemotherapy For Muscle Invasive Bladder Cancer Trial (ARCHER)

Read More
December 15, 2025 in Genitourinary (GU)

EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

Read More
October 20, 2025 in Genitourinary (GU)

S2427: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) (NCT# 07061964)

Read More
July 28, 2025 in Genitourinary (GU)

A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma – STRIKE (NCT06661720)

Read More
June 23, 2025 in Genitourinary (GU)

A032102: PREcision DIagnostics in prostate Cancer Treatment (PREDICT)

Read More
April 7, 2025 in Genitourinary (GU)

S2312: A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature (NCT# 06470243)

Read More
August 13, 2024 in Genitourinary (GU)

GU013

The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
Read More
May 20, 2024 in Genitourinary (GU)

MK5684

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and…
Read More
April 30, 2024 in Genitourinary (GU)

A032103

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Read More
October 11, 2022 in Genitourinary (GU)

GU012

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (NCT# 05327686)
Read More
August 26, 2022 in Genitourinary (GU)

EA8191

EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) (NCT04423211)
Read More
July 11, 2022 in Genitourinary (GU)

S1937

S1937: A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible…
Read More
July 11, 2022 in Genitourinary (GU)

S1931

S1931: PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931) (NCT#0451059)
Read More
July 11, 2022 in Genitourinary (GU)

S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer).
Read More
June 30, 2022 in Genitourinary (GU)

GU011

GU011: A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) (NCT# 05053152)
Read More
June 30, 2022 in Genitourinary (GU)

GU008

GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (NCT #04134260)
Read More
June 30, 2022 in Genitourinary (GU)

EA8192

EA8192: A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Read More
June 29, 2022 in Genitourinary (GU)

A031702

A031702: A phase II study of Ipilimumab, CabOzantinib, and NIvolumab in rare genitourinary Cancers (ICONIC) (NCT03866382)
Read More